共 45 条
- [41] Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial TRIALS, 2023, 24 (01)
- [42] Comparison of the Pharmacokinetics of a New 15-mg Modified-Release Tablet Formulation of Metoclopramide Versus a 10-mg Immediate-Release Tablet: A Single- and Multiple-Dose, Randomized, Open-Label, Parallel-Group Study in Healthy Mexican Male Volunteers CLINICAL THERAPEUTICS, 2011, 33 (05) : 630 - 643
- [43] Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804) JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 655 - 664
- [44] Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial HORMONE RESEARCH IN PAEDIATRICS, 2015, 83 (04): : 268 - 279
- [45] Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)